Cubist Systematic Strategies’s Biodexa Pharmaceuticals BDRX Stock Holding History

Cubist Systematic Strategies’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3	Closed	-$18.2K	–	3344
2023 Q2	$18.2K	Buy	+3	New	+$53.6K	﹤0.01%	3195

Other funds holding BDRX

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's BDRX Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2023, closing a stake of 3 shares — an estimated $18.2K sold.

Cubist Systematic Strategies first reported a position in BDRX in Q2 2023 and held it in 1 quarter. The position peaked at $18.2K in Q2 2023. 1 fund tracked by Wall St. Rank holds BDRX as of Q3 2023.

Cubist Systematic Strategies reported no remaining Biodexa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 3 Biodexa Pharmaceuticals shares in Q3 2023, an estimated $18.2K.
Cubist Systematic Strategies first reported a position in Biodexa Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Cubist Systematic Strategies's Biodexa Pharmaceuticals position peaked at $18.2K in Q2 2023.
1 fund tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.